Premium IGF-1 LR3 Peptide 1mg for Laboratory Research
The Onyx Biolabs IGF-1 LR3 Peptide 1mg (Insulin-like Growth Factor-1 Long Arg3) is a highly purified, synthetic protein and lengthened analogue of human IGF-1. Comprising 83 amino acids, this compound features a crucial 13-amino acid extension at the N-terminus and a substitution of Arginine for Glutamic Acid at position 3. These highly specific structural modifications are what make this compound a premier subject of study in the fields of cellular hyperplasia and musculoskeletal research.
At Onyx Biolabs, we maintain strict adherence to “research-grade” standards. This IGF-1 LR3 Peptide 1mg is subjected to rigorous independent testing to verify its structural integrity, ensuring that researchers receive only the highest fidelity compounds for their in-vitro cell culture assays and tissue regeneration models.
Mechanisms of Action: Evading IGF-Binding Proteins
In standard laboratory models, native IGF-1 has a very short half-life (approximately 20 minutes) because it is rapidly neutralized by Insulin-like Growth Factor Binding Proteins (IGFBPs). The unique structural modifications of the IGF-1 LR3 Peptide 1mg allow it to effectively evade these binding proteins. Consequently, researchers observe a significantly extended half-life (estimated between 20 to 30 hours) and substantially increased biological potency in vitro.
Researchers are primarily focused on the following biological pathways:
- Cellular Hyperplasia: Unlike compounds that merely increase the size of existing cells (hypertrophy), this peptide is heavily investigated for its ability to induce cellular hyperplasia—the actual division and creation of new cells within musculoskeletal tissue.
- Amino Acid Transport: Studies indicate it significantly upregulates the transport of amino acids and glucose into cells, providing the necessary metabolic fuel for rapid cellular synthesis and repair.
- Protein Degradation Inhibition: Research suggests it acts as a powerful anti-catabolic agent in cell cultures, actively downregulating the pathways responsible for protein breakdown and cellular apoptosis.
Why Source from Onyx Biolabs?
- Verified Analytical Excellence: Every batch undergoes strict High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry testing to guarantee ≥99% purity. Researchers can independently verify these metrics via our COA Lab Results.
- Domestic Operations: We dispatch all orders directly from our climate-controlled facility in Charlotte, NC. This ensures rapid transit times, eliminating the risk of customs seizures and international shipping degradation.
- Uncompromising Quality: Our peptides are strictly handled in sterile environments to preserve their delicate peptide bonds before ever reaching your laboratory.
Advanced Reconstitution & Storage Protocols
Due to its complex 83-amino acid chain, the lyophilized IGF-1 LR3 Peptide 1mg requires highly precise laboratory reconstitution techniques. While standard Bacteriostatic Water is suitable for immediate short-term assays, many researchers prefer to reconstitute this specific compound with a 0.6% Acetic Acid (AA) solution to maximize long-term stability and prevent the peptide chains from adhering to the glass vial, later diluting with Bacteriostatic Water as needed.
When introducing your chosen diluent, direct the needle against the inner glass wall of the vial. Allow the liquid to slide down gently to prevent the physical shearing of the long peptide sequence. Never shake or vigorously agitate the vial. Instead, gently roll the glass between your fingers until the powder is fully dissolved and the solution achieves optical clarity. Foaming indicates molecular fracturing and severely compromises the compound.
Storage Guidelines: Prior to reconstitution, the lyophilized powder should be stored at -20°C. Once reconstituted, the liquid solution must be refrigerated at 4°C. Researchers should always utilize appropriate personal protective equipment (PPE), including nitrile gloves, during handling.
Note: This compound is strictly for in-vitro laboratory research use only and is not for human consumption, diagnostic, or therapeutic purposes.
References:
- Tomas FM, et al. IGF-I variants which bind poorly to IGF-binding proteins show more potent and prolonged hypoglycaemic action than native IGF-I. Journal of Endocrinology. 1993.
- Tomas FM, et al. Increased weight gain, nitrogen retention and muscle protein synthesis following treatment of diabetic rats with insulin-like growth factor (IGF)-I and des(1-3)IGF-I. Biochemical Journal. 1991.
